Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
August, 2026
August 2026
M T W T F S S
 12
3456789
10111213141516
17181920212223
24252627282930
31  
Dhinesh Selvaraju: FDA Expands Access to HYMPAVZI in Hemophilia
Dhinesh Selvaraju/LinkedIn
Jul 2, 2026, 19:26

Dhinesh Selvaraju: FDA Expands Access to HYMPAVZI in Hemophilia

Dhinesh Selvaraju, Clinical Research Assistant at Yuva Intern by Henry Harvin, shared a post on LinkedIn:

“FDA Approval (2026): Expanded Indication for HYMPAVZI (marstacimab-hncq) in Hemophilia A or B – Broader Patient Access Including Inhibitors and Younger Pediatrics

The U.S. Food and Drug Administration approved an expanded indication for Pfizer’s HYMPAVZI on June 8, 2026, providing a non-factor, once-weekly subcutaneous option to a wider population of patients with hemophilia.

FDA Approval Date (Expanded Indication): June 8, 2026

Drug Details

Brand Name: HYMPAVZI

Generic Name: marstacimab-hncq

Dosage Form: Subcutaneous injection

Indication (Expanded)

Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and pediatric patients 6 years of age and older with hemophilia A (congenital factor VIII deficiency) with or without factor VIII inhibitors, or hemophilia B (congenital factor IX deficiency) with or without factor IX inhibitors.

Mechanism of Action

HYMPAVZI is a human monoclonal antibody that inhibits the Kunitz 2 domain of tissue factor pathway inhibitor (TFPI). By blocking TFPI, it increases availability of factor Xa, promoting thrombin generation and rebalancing hemostasis without replacing the missing clotting factor.

Clinical Evidence

Supported by data from the phase 3 BASIS trial and other studies demonstrating bleed reduction in patients with and without inhibitors.

Offers once-weekly dosing with no routine laboratory monitoring required for treatment.

Provides bleed protection across hemophilia A and B, including difficult-to-treat populations with inhibitors.

Safety and Monitoring

Common adverse events consistent with hemophilia population. Monitor for thrombotic events as with other hemostatic agents. No routine coagulation laboratory monitoring needed for dosing adjustments.

Why this approval is important

This expansion significantly broadens access to a convenient, non-factor therapy for patients with hemophilia A or B, including those with inhibitors and younger pediatric patients (ages 6–11).

It addresses unmet needs in hemostasis management by offering reduced treatment burden while maintaining effective bleed prevention — a clinically meaningful advancement for practitioners supporting comprehensive care in hemophilia.”

Dhinesh Selvaraju: FDA Expands Access to HYMPAVZI in Hemophilia

Stay updated with Hemostasis Today.

Dhinesh Selvaraju Health Hematology Hemophilia Hemophilia A Hemophilia B Hemostasis Hemostasis News Hemostasis Today HYMPAVZI marstacimab-hncq Medicine
NewsFeed